Literature DB >> 11258408

Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm.

T Qu1, Y Wang, Z Zhu, M Rusckowski, D J Hnatowich.   

Abstract

Relatively few studies comparing different methods of labelling peptides with 99Tcm have been reported. In this investigation, we evaluated the influence of three chelators on the in vitro and in vivo properties of two small, similar peptides (HNE2 and HNE4) labelled with 99Tcm. Both peptides were labelled with hydrazinonicotinamide (HYNIC) (tricine) at pH 5-6 and with diethylenetriaminepentaacetic acid (DTPA) and mercaptoacetyltriglycine (MAG3) at both pH 5-6 and 7-8. All ten preparations were brought to pH 7.2 immediately after labelling. Each preparation labelled well and control labelling showed each label to be attached specifically at chelation sites. Analysis of 37 degrees C human serum incubates showed little evidence of label instability but high protein binding in several cases. The stability of 99Tcm to cysteine challenge for labelled DTPA- and MAG3-peptides was similar but lower than that for the HYNIC-peptides. Reverse phase HPLC of the DTPA-peptides, but not the MAG3-peptides, showed different 99Tcm species depending on labelling pH. The 3 h biodistributions in normal mice were generally independent of labelling pH for both MAG3-peptides but were heavily influenced by labelling pH for both DTPA-peptides. While significant differences in biodistribution for the same labelling method were evident between peptides, as expected, far larger differences in the case of both peptides resulted from changing chelators and, in the case of DTPA, changing the labelling method. In summary, the chelators and labelling methods influenced the biodistribution of 99Tcm in a characteristic fashion common to both peptides. Differences in biodistribution due to the different peptides were relatively small and generally lost in the much larger differences due to chelator and labelling method. In conclusion, it may be important to compare chelators and labelling methods before selecting a 99Tcm labelling method for any particular peptide.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11258408     DOI: 10.1097/00006231-200102000-00013

Source DB:  PubMed          Journal:  Nucl Med Commun        ISSN: 0143-3636            Impact factor:   1.690


  6 in total

1.  Imaging of HER2-expressing tumours using a synthetic Affibody molecule containing the 99mTc-chelating mercaptoacetyl-glycyl-glycyl-glycyl (MAG3) sequence.

Authors:  Torun Engfeldt; Anna Orlova; Thuy Tran; Alexander Bruskin; Charles Widström; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2006-12-05       Impact factor: 9.236

2.  68Ga chelating bioorthogonal tetrazine polymers for the multistep labeling of cancer biomarkers.

Authors:  Brandon Nichols; Zhengtao Qin; Jun Yang; David R Vera; Neal K Devaraj
Journal:  Chem Commun (Camb)       Date:  2014-03-04       Impact factor: 6.222

3.  Comparison between two labeled agents in mice using a coinjection-ratio approach in contrast to a conventional group approach.

Authors:  Shuping Dou; Yuzhen Wang; Bruce Barton; Ling Chen; Mary Rusckowski; Leonard D Shultz; Dale L Greiner; Guozheng Liu
Journal:  Nucl Med Biol       Date:  2013-10-09       Impact factor: 2.408

4.  (186)Re-maSGS-Z (HER2:342), a potential Affibody conjugate for systemic therapy of HER2-expressing tumours.

Authors:  Anna Orlova; Thuy A Tran; Torun Ekblad; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-09-22       Impact factor: 9.236

5.  99mTc-chelator engineering to improve tumour targeting properties of a HER2-specific Affibody molecule.

Authors:  Torun Engfeldt; Thuy Tran; Anna Orlova; Charles Widström; Joachim Feldwisch; Lars Abrahmsen; Anders Wennborg; Amelie Eriksson Karlström; Vladimir Tolmachev
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-06-13       Impact factor: 9.236

6.  Synthesis of multidentate ligands with amido or amino donor groups for the preparation of rhenium and technetium radiopharmaceuticals.

Authors:  S M D Al-Nuzal; H M A-K Al-Azzawi; Z M J Al-Mosawy
Journal:  J Radioanal Nucl Chem       Date:  2012-12-11       Impact factor: 1.371

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.